META Pharmaceuticals Inc. was founded in Shenzhen, China
Completed USD 6.1 million Seed financing
Completed USD 9.0 million Pre-Series A financing
Moved into Shenzhen Hong Kong International Biomedical Industrial Park, Shenzhen, China
Founders Dr. Ke Xu and Dr. Anjin Xianyu were featured on the cover of Impact Magazine from Weill Cornell Medicine for their pioneering innovations in immunometabolism
META-001-PH granted FDA Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD)
Completed approximately USD 6.0 million Series A1 financing
MP-5342 formally nominated as a clinical development candidate for inflammatory bowel disease